Br J Surg. 2021 Jan 27;108(1):88-96. doi: 10.1093/bjs/znaa051.
Surgical services are preparing to scale up in areas affected by COVID-19. This study aimed to evaluate the association between preoperative SARS-CoV-2 testing and postoperative pulmonary complications in patients undergoing elective cancer surgery.
This international cohort study included adult patients undergoing elective surgery for cancer in areas affected by SARS-CoV-2 up to 19 April 2020. Patients suspected of SARS-CoV-2 infection before operation were excluded. The primary outcome measure was postoperative pulmonary complications at 30 days after surgery. Preoperative testing strategies were adjusted for confounding using mixed-effects models.
Of 8784 patients (432 hospitals, 53 countries), 2303 patients (26.2 per cent) underwent preoperative testing: 1458 (16.6 per cent) had a swab test, 521 (5.9 per cent) CT only, and 324 (3.7 per cent) swab and CT. Pulmonary complications occurred in 3.9 per cent, whereas SARS-CoV-2 infection was confirmed in 2.6 per cent. After risk adjustment, having at least one negative preoperative nasopharyngeal swab test (adjusted odds ratio 0.68, 95 per cent confidence interval 0.68 to 0.98; P = 0.040) was associated with a lower rate of pulmonary complications. Swab testing was beneficial before major surgery and in areas with a high 14-day SARS-CoV-2 case notification rate, but not before minor surgery or in low-risk areas. To prevent one pulmonary complication, the number needed to swab test before major or minor surgery was 18 and 48 respectively in high-risk areas, and 73 and 387 in low-risk areas.
Preoperative nasopharyngeal swab testing was beneficial before major surgery and in high SARS-CoV-2 risk areas. There was no proven benefit of swab testing before minor surgery in low-risk areas.
外科服务正准备在受 COVID-19 影响的地区扩大规模。本研究旨在评估在接受择期癌症手术的患者中,术前 SARS-CoV-2 检测与术后肺部并发症之间的关系。
这是一项国际队列研究,纳入了截至 2020 年 4 月 19 日在受 SARS-CoV-2 影响地区接受择期癌症手术的成年患者。在手术前怀疑感染 SARS-CoV-2 的患者被排除在外。主要观察指标是术后 30 天的肺部并发症。使用混合效应模型调整混杂因素来调整术前检测策略。
在 8784 名患者(432 家医院,53 个国家)中,有 2303 名患者(26.2%)接受了术前检测:1458 名(16.6%)进行了拭子检测,521 名(5.9%)仅进行了 CT 检查,324 名(3.7%)进行了拭子和 CT 检查。肺部并发症发生率为 3.9%,而 SARS-CoV-2 感染率为 2.6%。在风险调整后,至少有一次术前鼻咽拭子检测阴性(调整后的优势比 0.68,95%置信区间 0.68 至 0.98;P=0.040)与肺部并发症发生率较低相关。在大手术前和 SARS-CoV-2 14 天病例报告率较高的地区进行拭子检测是有益的,但在小手术前或低风险地区则不然。为了预防一次肺部并发症,在高风险地区进行大手术或小手术前,需要拭子检测的人数分别为 18 人和 48 人,而在低风险地区,需要拭子检测的人数分别为 73 人和 387 人。
术前鼻咽拭子检测在大手术前和高 SARS-CoV-2 风险地区是有益的。在低风险地区,小手术前进行拭子检测没有益处。